Precision Nutrition and Metabolic Function
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Brittney Mason
- Phone Number: 314-273-1879
- Email: nutritionresearch@wustl.edu
Study Locations
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Metabolically healthy lean subjects must have a body mass index (BMI) 18.5-24.9 kg/m², intrahepatic triglyceride (IHTG) content ≤5%, serum triglyceride (TG) concentration <150 mg/dl, fasting plasma glucose concentration <100 mg/dl, 2-hr oral glucose tolerance test (OGTT) plasma glucose concentration ≤140 mg/dl, and hemoglobin A1C (HbA1C) ≤5.6%.
- Metabolically healthy obese subjects must have a BMI 30-49.9 kg/m²; IHTG content ≤5%, serum TG concentration <150 mg/dl, fasting plasma glucose concentration <100 mg/dl, 2-hr OGTT plasma glucose concentration ≤140 mg/dl, and HbA1C ≤5.6%.
- Metabolically unhealthy obese subjects must have a BMI 30-49.9 kg/m²; IHTG content ≥5.6% and fasting plasma glucose concentration ≥100 mg/dl or 2-hr OGTT plasma glucose concentration ≥140 mg/dl or HbA1C ≥5.7%.
Exclusion Criteria:
- medical, surgical, or biological menopause;
- previous bariatric surgery where the gastrointestinal tract is reconstructed such as Roux-en-Y, sleeve gastrectomy and biliopancreatic diversion surgeries;
- laparoscopic adjustable gastric band (lab band) surgery within the last 3 years;
- structured exercise ≥250 min per week (e.g., brisk walking);
- unstable weight (>4% change during the last 2 months before entering the study);
- significant organ system dysfunction (e.g., diabetes requiring medications, severe pulmonary, kidney or cardiovascular disease);
- cancer or cancer that has been in remission for <5 years;
- polycystic ovary syndrome;
- major psychiatric illness;
- conditions that render subject unable to complete all testing procedures (e.g., severe ambulatory impairments, limb amputations, or metal implants that interfere with imaging procedures; coagulation disorders);
- severe anemia;
- regular use of tobacco products;
- excessive consumption of alcohol (≥3 drinks/day for men and ≥2 drinks/day for women);
- use of medications that are known to affect the study outcome measures (e.g., steroids, non-statin lipid-lowering medications) or increase the risk of study procedures (e.g., anticoagulants) and that cannot be temporarily discontinued for this study;
- use of antibiotics in last 60 days;
- pregnant or lactating women;
- vegans, vegetarians, those with lactose intolerance and/or severe aversions/sensitivities to eggs, fish, nuts, wheat and soy, and/or any individuals with food allergies that induce an anaphylactic response;
- persons who are not able to grant voluntary informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Metabolically healthy lean
Metabolically normal lean - Lean individuals that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content.
|
Annual follow-up testing with no restrictions on dietary intake during periods between annual testing.
|
|
Experimental: Metabolically healthy obese - Mediterranean diet
Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content randomized to the Mediterranean diet group.
|
Annual follow-up testing with no restrictions on dietary intake during periods between annual testing.
A Mediterranean-type diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.
|
|
Experimental: Metabolically healthy obese - Low-carbohydrate ketogenic diet
Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content randomized to the low-carbohydrate ketogenic diet group.
|
Annual follow-up testing with no restrictions on dietary intake during periods between annual testing.
A low-carbohydrate, ketogenic diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.
|
|
Experimental: Metabolically normal obese - Low-fat diet
Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content randomized to the low-fat diet group.
|
Annual follow-up testing with no restrictions on dietary intake during periods between annual testing.
A low-fat diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.
|
|
Experimental: Metabolically unhealthy obese - Mediterranean diet
Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver randomized to the Mediterranean diet group.
|
Annual follow-up testing with no restrictions on dietary intake during periods between annual testing.
A Mediterranean-type diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.
|
|
Experimental: Metabolically unhealthy obese - Low-carbohydrate ketogenic diet
Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver randomized to the low-carbohydrate, ketogenic diet group.
|
Annual follow-up testing with no restrictions on dietary intake during periods between annual testing.
A low-carbohydrate, ketogenic diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.
|
|
Experimental: Metabolically unhealthy obese - Low-fat diet
Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver randomized to the low-fat diet group.
|
Annual follow-up testing with no restrictions on dietary intake during periods between annual testing.
A low-fat diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Insulin sensitivity
Time Frame: Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
Whole-body insulin sensitivity will be assessed by using the hyperinsulinemic-euglycemic clamp procedure
|
Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
|
Change in insulin sensitivity
Time Frame: Before and after 4-8 weeks of weight maintenance in metabolically healthy and unhealthy obese subjects randomized to follow a Mediterranean, low-carbohydrate or low-fat diet
|
Whole-body insulin sensitivity will be assessed by using the hyperinsulinemic-euglycemic clamp procedure
|
Before and after 4-8 weeks of weight maintenance in metabolically healthy and unhealthy obese subjects randomized to follow a Mediterranean, low-carbohydrate or low-fat diet
|
|
Change in insulin sensitivity
Time Frame: Performed annually for 5 years
|
Whole-body insulin sensitivity will be assessed by using the hyperinsulinemic-euglycemic clamp procedure
|
Performed annually for 5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
24-hour glucose concentrations
Time Frame: Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
Plasma glucose concentrations will be evaluated from frequent blood samples over a 24 h period
|
Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
|
Change in 24-hour glucose concentrations
Time Frame: Before and after 4-8 weeks of weight maintenance in metabolically healthy and unhealthy obese subjects randomized to follow a Mediterranean, low-carbohydrate or low-fat diet
|
Plasma glucose concentrations will be evaluated from frequent blood sampling over a 24 h period
|
Before and after 4-8 weeks of weight maintenance in metabolically healthy and unhealthy obese subjects randomized to follow a Mediterranean, low-carbohydrate or low-fat diet
|
|
Change in 24-hour glucose concentrations
Time Frame: Performed annually for 5 years
|
Plasma glucose concentrations will be evaluated from frequent blood sampling over a 24 h period
|
Performed annually for 5 years
|
|
24-hour hormone concentrations
Time Frame: Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
Plasma hormone concentrations will be evaluated from frequent blood sampling over a 24 h period
|
Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
|
Change in 24-hour hormone concentrations
Time Frame: Before and after 4-8 weeks of weight maintenance in metabolically healthy and unhealthy obese subjects randomized to follow a Mediterranean, low-carbohydrate or low-fat diet
|
Plasma hormone concentrations will be evaluated from frequent blood samples over a 24 h period
|
Before and after 4-8 weeks of weight maintenance in metabolically healthy and unhealthy obese subjects randomized to follow a Mediterranean, low-carbohydrate or low-fat diet
|
|
Change in 24-hour hormone concentrations
Time Frame: Performed annually for 5 years
|
Plasma hormone concentrations will be evaluated from frequent blood samples over a 24 h period
|
Performed annually for 5 years
|
|
β-cell function
Time Frame: Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
β-cell function will be assessed from a modified oral glucose tolerance test
|
Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
|
Change in β-cell function
Time Frame: Performed annually for 5 years
|
β-cell function will be assessed from a modified oral glucose tolerance test
|
Performed annually for 5 years
|
|
Insulin clearance
Time Frame: Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
Insulin clearance will be assessed from a modified oral glucose tolerance test and hyperinsulinemic-euglycemic clamp procedure
|
Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
|
Change in Insulin clearance
Time Frame: Performed annually for 5 years
|
Insulin clearance will be assessed from a modified oral glucose tolerance test and hyperinsulinemic-euglycemic clamp procedure
|
Performed annually for 5 years
|
|
Fat mass and fat free mass
Time Frame: Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
Fat mass and fat free mass will be assessed using dual-energy x-ray absorptiometry (DXA)
|
Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
|
Change in fat mass and fat free mass
Time Frame: Before and after 4-8 weeks of weight maintenance in metabolically healthy and unhealthy obese subjects randomized to follow a Mediterranean, low-carbohydrate or low-fat diet
|
Fat mass and fat free mass will be assessed using dual-energy x-ray absorptiometry (DXA)
|
Before and after 4-8 weeks of weight maintenance in metabolically healthy and unhealthy obese subjects randomized to follow a Mediterranean, low-carbohydrate or low-fat diet
|
|
Change in fat mass and fat free mass
Time Frame: Performed annually for 5 years
|
Fat mass and fat free mass will be assessed using dual-energy x-ray absorptiometry (DXA)
|
Performed annually for 5 years
|
|
Exosome-mediated intercellular signaling
Time Frame: Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
Signaling between cells and organs will be examined by isolating exosomes (small extracellular vesicles) from blood and adipose tissue
|
Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
|
Change in exosome-mediated intercellular signaling
Time Frame: Before and after 4-8 weeks of weight maintenance in metabolically healthy and unhealthy obese subjects randomized to follow a Mediterranean, low-carbohydrate or low-fat diet
|
Signaling between cells and organs will be examined by isolating exosomes (small extracellular vesicles) from blood and adipose tissue
|
Before and after 4-8 weeks of weight maintenance in metabolically healthy and unhealthy obese subjects randomized to follow a Mediterranean, low-carbohydrate or low-fat diet
|
|
Change in exosome-mediated intercellular signaling
Time Frame: Performed annually for 5 years
|
Signaling between cells and organs will be examined by isolating exosomes (small extracellular vesicles) from blood and adipose tissue
|
Performed annually for 5 years
|
|
Intrahepatic triglyceride content
Time Frame: Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
Intrahepatic triglyceride content will be assessed by magnetic resonance imagining (MRI)
|
Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
|
Change in intra-hepatic triglyceride content
Time Frame: Before and after 4-8 weeks of weight maintenance in metabolically healthy and unhealthy obese subjects randomized to follow a Mediterranean, low-carbohydrate or low-fat diet
|
Intra-hepatic triglyceride content will be assessed by magnetic resonance imagining (MRI)
|
Before and after 4-8 weeks of weight maintenance in metabolically healthy and unhealthy obese subjects randomized to follow a Mediterranean, low-carbohydrate or low-fat diet
|
|
Change in intra-hepatic triglyceride content
Time Frame: Performed annually for 5 years
|
Intra-hepatic triglyceride content will be assessed by magnetic resonance imagining (MRI)
|
Performed annually for 5 years
|
|
Abdominal adipose tissue volumes
Time Frame: Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
Abdominal subcutaneous and intra-abdominal adipose tissue volumes will be assessed by magnetic resonance imagining (MRI)
|
Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
|
Change in abdominal adipose tissue volumes
Time Frame: Before and after 4-8 weeks of weight maintenance in metabolically healthy and unhealthy obese subjects randomized to follow a Mediterranean, low-carbohydrate or low-fat diet
|
Abdominal subcutaneous and intra-abdominal adipose tissue volumes will be assessed by magnetic resonance imagining (MRI)
|
Before and after 4-8 weeks of weight maintenance in metabolically healthy and unhealthy obese subjects randomized to follow a Mediterranean, low-carbohydrate or low-fat diet
|
|
Change in abdominal adipose tissue volumes
Time Frame: Performed annually for 5 years
|
Abdominal subcutaneous and intra-abdominal adipose tissue volumes will be assessed by magnetic resonance imagining (MRI)
|
Performed annually for 5 years
|
|
Leg adipose tissue volumes
Time Frame: Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
Thigh and calf adipose tissue volumes will be assessed by magnetic resonance imagining (MRI)
|
Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
|
Change in leg adipose tissue volumes
Time Frame: Before and after 4-8 weeks of weight maintenance in metabolically healthy and unhealthy obese subjects randomized to follow a Mediterranean, low-carbohydrate or low-fat diet
|
Thigh and calf adipose tissue volumes will be assessed by magnetic resonance imagining (MRI)
|
Before and after 4-8 weeks of weight maintenance in metabolically healthy and unhealthy obese subjects randomized to follow a Mediterranean, low-carbohydrate or low-fat diet
|
|
Change in leg adipose tissue volumes
Time Frame: Performed annually for 5 years
|
Thigh and calf adipose tissue volumes will be assessed by magnetic resonance imagining (MRI)
|
Performed annually for 5 years
|
|
Gut microbiome
Time Frame: Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
Gut microbiota, meta-transcriptome (bacterial RNA sequencing to determine what proteins can be made by the microbiota) and the meta-metabolome (metabolites made by the microbiota) will be assessed
|
Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
|
Change in gut microbiome
Time Frame: Before and after 4-8 weeks of weight maintenance in metabolically healthy and unhealthy obese subjects randomized to follow a Mediterranean, low-carbohydrate or low-fat diet
|
Gut microbiota, meta-transcriptome (bacterial RNA sequencing to determine what proteins can be made by the microbiota) and the meta-metabolome (metabolites made by the microbiota) will be assessed
|
Before and after 4-8 weeks of weight maintenance in metabolically healthy and unhealthy obese subjects randomized to follow a Mediterranean, low-carbohydrate or low-fat diet
|
|
Change in gut microbiome
Time Frame: Performed annually for 5 years
|
Gut microbiota, meta-transcriptome (bacterial RNA sequencing to determine what proteins can be made by the microbiota) and the meta-metabolome (metabolites made by the microbiota) will be assessed
|
Performed annually for 5 years
|
|
Carotid artery intima media thickness
Time Frame: Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
Carotid artery intima media thickness will be assessed by ultrasound imaging
|
Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
|
Change in carotid artery intima media thickness
Time Frame: Performed annually for 5 years
|
Carotid artery intima media thickness will be assessed by ultrasound imaging
|
Performed annually for 5 years
|
|
Cardiac structure and function
Time Frame: Baseline only (cross-sectional comparison of metabolically healthy obese and metabolically unhealthy obese subjects).
|
Ultrasound techniques will be used to assess cardiac structure and function
|
Baseline only (cross-sectional comparison of metabolically healthy obese and metabolically unhealthy obese subjects).
|
|
Change in cardiac structure and function
Time Frame: Performed annually for 5 years in metabolically healthy obese and metabolically unhealthy obese subjects.
|
Ultrasound techniques will be used to assess cardiac structure and function
|
Performed annually for 5 years in metabolically healthy obese and metabolically unhealthy obese subjects.
|
|
Endothelial function
Time Frame: Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
Endothelial function will be assessed using a non-invasive device (EndoPat 2000) in response to reactive hyperemia.
|
Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
|
Change in endothelial function
Time Frame: Performed annually for 5 years
|
Endothelial function will be assessed using a non-invasive device (EndoPat 2000) in response to reactive hyperemia.
|
Performed annually for 5 years
|
|
Arterial stiffness
Time Frame: Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
Arterial stiffness will be assessed using a non-invasive device (SphygmoCor)
|
Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
|
Change in arterial stiffness
Time Frame: Performed annually for 5 years
|
Arterial stiffness will be assessed using a non-invasive device (SphygmoCor)
|
Performed annually for 5 years
|
|
Transcriptome in blood, muscle and adipose tissue
Time Frame: Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
The transcriptome (all RNA that are responsible for making proteins from DNA templates) will be evaluated by using RNA sequencing techniques
|
Baseline only (cross-sectional comparison of metabolically healthy lean, metabolically healthy obese and metabolically unhealthy obese subjects).
|
|
Change in transcriptome in blood, muscle and adipose tissue
Time Frame: Performed annually for 5 years
|
The transcriptome (all RNA that are responsible for making proteins from DNA templates) will be evaluated by using RNA sequencing techniques
|
Performed annually for 5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Samuel Klein, MD, Washington University School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nutrition Disorders
- Metabolic Diseases
- Overnutrition
- Body Weight
- Glucose Metabolism Disorders
- Hyperinsulinism
- Overweight
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Obesity
- Insulin Resistance
- Therapeutics
- Diet, Food, and Nutrition
- Physiological Phenomena
- Nutritional Physiological Phenomena
- Diet, Plant-Based
- Diet Therapy
- Nutrition Therapy
- Diet
- Diet, Carbohydrate-Restricted
- Diet, Mediterranean
- Diet, Ketogenic
- Diet, Fat-Restricted
Other Study ID Numbers
Other Study ID Numbers
- 201908237
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.